Skip to main content

Sleep Disorder Therapeutics Market Forecasted to Grow at Steady Pace During 2015-2021

Sleep disorders include a variety of complications related to sleep and have a high prevalence across the globe. Based on these complications, sleep disorders can be classified into three categories- lack of sleep which includes insomnia, excessive sleep which includes narcolepsy and disturbed sleep which include sleep apnea and Rapid eye movement (REM) disorder. Insomnia may arise as result of unhealthy diet, emotional dreams, stress, and many other factors.
Insomnia may affect reaction time towards common stimulus, hand-eye coordination, memory, and disturb daily life. Narcolepsy is a disorder that causes uncontrolled sleep at time period lasting less than minute or more than an hour. It has also been found that patients with narcolepsy experience sleep attacks more often during pregnancy, stress or ill health.
Request For Report Sample@ https://www.persistencemarketresearch.com/samples/5714
Usually narcolepsy is a genetic disease, but it has also been found to develop as a result of some neurological disorders or severe brain damage. REM sleep behavior disorder involves abnormal behavior in sleep. In this disorder, a patient dreaming about running, may run while still asleep. Sleep apnea is obstructed breathing during sleep.
According to a press release in March 2014 by World Association of Sleep Medicine, 45% of the global population suffers from some form of sleep disorder. It also mentions that approximately 25% male and 10% females in the U.S. suffer from sleep apnea. This high prevalence suggests an opportunity for a large therapeutics market.
Currently marketed drugs include Sanofi-Aventis manufactured Ambien (zolpidem), Sunovion Pharmaceuticals Inc.’s Lunesta (eszopiclone), Takeda Pharmaceutical’s Rozerem (ramelteon), Somaxon Pharmaceuticals, Inc.’s Silenor (doxepine) and various others. Over-the-counter drugs are also available for treating sleep disorder; these include
  • Nytol,
  • Sominex,
  • Compoz, and
  • Unisom.
Merck’s Suvorexant drug is an orexin receptor agonist which is under Phase III trial. Other companies involved in the drug development of sleep disorder include
  • Vanda Pharmaceuticals,
  • Eli Lilly,
  • GlaxoSmithKline and
  • Neurim Pharmaceuticals.
Request For Report Table of Content (TOC)@ https://www.persistencemarketresearch.com/toc/5714
Key geographies evaluated in this report are:
  • North America
    • U.S
    • Canada
  • Europe
    • France, Germany, Italy, Spain, and the UK
    • Eastern Europe
    • CIS
  • APAC
    • China
    • India
    • Japan
    • Australia
    • Others
  • Latin America
    • Argentina
    • Brazil
    • Others
Key features of this report
  • Drivers, restraints, and challenges shaping the Sleep Disorder Therapeutics market dynamics
  • Latest innovations and key events in the industry
  • Analysis of business strategies of the top players
  • Sleep Disorder Therapeutics market estimates and forecasts(2015 -2021)
Know More About Report@ https://www.persistencemarketresearch.com/market-research/sleep-disorder-therapeutics-market.asp

Comments

Popular posts from this blog

Development: Aerospace 3D Printing Market Strategy Planning by Top Manufacturers

  Aerospace 3D Printing Market Analysis 2026: According to a study of the Research Dive,  aerospace 3D printing market  forecast shall cross  $5,933.4 million by 2026 , growing at a  CAGR of 26.8%  during forecast period. Aerospace 3D printing is primarily used to increase the efficiency of A&D supply chain, reduction of storage costs of inventory and waste production materials. Furthermore, the Aerospace 3D printing industry is focusing more on creating parts of aircraft that are lighter and stronger than parts made by using traditional manufacturing. Astonishing advantages of 3D printings in the supply chain of the aerospace and defense industry are projected to surge in the global market. In addition, the financial support provided by the government and non-government organizations across the globe is also driving the 3D printing in aerospace industry. For instance,   National Aerospace Technology Exploitation Programme grants £140,000 funds for...

Cloud Applications Market Foraying into Emerging Economies 2030

  The COVID-19 pandemic has affected various business sectors across the globe. However, the cloud application market has observed a rapid growth in the recent months. Sudden outbreak of the COVID-19 has created a massive opportunity for cloud applications in the 1Q of 2020. For instance, organizations around the world have adopted the work from home concept, in which cloud has given organizations various applications to remotely access the data, build and run crucial applications and allows to work with the partners and employees across the globe. The healthcare sector has been observed to adopt various cloud applications in the recent days; this is majorly to maintain huge data base of the patients which helps the governing bodies as well to keep a close watch on the patients even after they have recovered and discharged.  During this unique situation, our analysts are helping our clients in understanding the  impact of COVID-19 on the cloud application market  by ...

What is the current and future scenario of Oxygen Cylinder And Concentrator?

  According to a study,  Oxygen Cylinder and Concentrator Market  by Research Dive, the market is expected to reach $5,052.1 million by 2026, registering a CAGR of 8.7% from 2019-2026. Growing utilization from different applications and increasing focus on consumption are some of the oxygen cylinder and concentrator market drivers. The oxygen cylinder and concentrator market is primarily dominated by growing utilization from different applications, for instance, healthcare, pharmaceutical & biotechnology and manufacturing industries. According to American Academy of Allergy, Asthma & Immunology (AAAAI), about 320 million people worldwide are diagnosed with Asthma, of which about 255000 are suffering from the disease. However, it is estimated that by the end of 2026, the number of asthma patients would continue to grow by more than 102 million. This factors further enhance the market in healthcare and medical segment. Additionally, rising demands for adventure spor...